Document is current
Any future updates will be listed below
-
Authors
Oya, Mototsugu
Yasuoka, Shotaro
Tokudome, Takuto https://orcid.org/0009-0003-7091-5898
Minegishi, Toshihiko
Hamada, Masahiro
Ozaki, Masahiko
Maekawa, Shinichiroh
Ito, Yuichiro
-
Funding
Funding for this research was provided by:
MSD K.K.
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 18 January 2025
First Online: 29 April 2025
Declarations
:
: M Oya has received speaker fees from Pfizer, Bayer, Ono Pharmaceutical, Bristol-Myers Squibb, Takeda Pharmaceutical, MSD, Merck Biopharma, and Eisai; research funding/grants from Eisai, MSD, and Ono Pharmaceutical; and donations from Takeda Pharmaceutical, Bayer, and Eisai. SY, TT, M Ozaki, and SM are employees of MSD and hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA. TM is an employee of MSD and holds stock or stock options in Merck & Co., Inc., Rahway, NJ, USA, and GlaxoSmithKline. MH is an employee of MSD and holds stock or stock options in Merck & Co., Inc., Rahway, NJ, USA, and Organon & Co. YI is an employee of MSD and holds stock or stock options in Merck & Co., Inc., Rahway, NJ, USA, and Bayer AG.
